Lundbeck eyes progress in 2022, disappoints compared to consensus

On Wednesday morning, Lundbeck has publicized its full-year financial figures for 2021. Sales of core products grew by 15 percent, but the company is still handing in results slightly below expectations.
Photo: Jens Dresling
Photo: Jens Dresling
by marketwire, translated by daniel pedersen

On Wednesday, pharmaceutical firm Lundbeck has released its full-year financial figures for 2021.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading